Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...

The agency has cleared Otezla (apremilast) for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for an estimated eight ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...

Johnson & Johnson’s (J&J) Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults ...

Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.

Horsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration ...

Several types of psoriasis may affect your arms, but plaque psoriasis is the most common. The earliest sign may be a small bump, but the hallmark symptoms are inflammation and thick patches of skin ...

Time is a scarce resource at the doctor’s office, with the average visit lasting nearly 19 minutes, according to 2023 research published in Journal of the American Medical Association Health Forum.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...